54-year-old man with cough and positive IGRA
A 54-year-old man with rheumatoid arthritis is seen for follow-up. His arthritis is well-controlled with adalimumab, which he has taken for three years. As part of routine annual screening, an interferon-gamma release assay (IGRA) is positive. He reports a two-month history of increased fatigue and a mild, nonproductive cough. He also mentions intermittent night sweats for the past month, which he describes as 'making his shirt damp' but not requiring him to change his clothes. He denies fever or weight loss. He works as an accountant. A chest radiograph obtained last week is reviewed and shows bibasilar linear scarring, reported as unchanged from a study two years prior. Temperature is 37.4°C (99.3°F), blood pressure is 128/76 mmHg, heart rate is 84/min, and respirations are 16/min. Oxygen saturation is 98% on room air. Lungs are clear to auscultation. Which of the following is the most appropriate next step in management?
See the answer and explanation below:
Post-Call Recovery Reads
Finished your notes? Time to swap the pager for a crown. Kingdoms of Silent Sorrows is the ultimate 'brain-break', a high-stakes fantasy featuring a Fae princess, a Vampire king, and an enemies-to-lovers arc that will actually make you forget about your rounding list. No p-values, just fated mates and forbidden magic.
View on AmazonThe Correct Answer
D
Explanation
Clinical Pearl:
Any patient with a positive tuberculosis screening test (IGRA or TST) and any symptoms concerning for active disease (such as cough, fever, night sweats, or weight loss) must undergo evaluation to rule out active TB before initiating treatment for latent infection. This is especially critical in immunocompromised patients.
Explanation:
This patient on a TNF-alpha inhibitor has a positive IGRA and constitutional symptoms (fatigue, night sweats, cough), raising suspicion for active tuberculosis (TB) disease. According to current infectious disease society guidance, active TB must be excluded before initiating treatment for latent TB infection (LTBI), as monotherapy for active disease can lead to drug resistance. The most appropriate next step in a patient with respiratory symptoms is to obtain sputum samples for microbiologic testing. Starting treatment with isoniazid and pyridoxine is incorrect because it is a regimen for LTBI and would be inappropriate and potentially dangerous if the patient has active disease. Discontinuing adalimumab may be necessary if active TB is diagnosed, but the immediate priority is to establish the diagnosis; repeating the IGRA is not useful as it does not differentiate active from latent infection. Reassurance is inappropriate given the combination of immunosuppression, a positive IGRA, and new constitutional symptoms. While a chest CT scan is more sensitive than a radiograph, obtaining sputum for AFB smear and culture is the most direct and specific method to diagnose active pulmonary TB and should be the priority.
See you tomorrow morning!